Bharat Biotech gets DCGI nod for phase 3 trials of nasal Covid vaccine
The trials will evaluate the nasal vaccine for both the primary dose schedule as well as the booster one, Bharat Biotech said. Intranasal vaccines are easier to administer in mass immuniaation campaigns and help reduce or stop transmission, the company said. Bharat Biotech on Friday received regulatory approval from the Drugs Controller General of India … Read more